Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Climate leaders are talking about 'overshoot' into warming danger zone. Here's what it means - 2Island Travel Guide: Must-Visit Objections for 2024
- 3Go on A Careful spending plan: Modest Objections for Your List of must-dos
- 4Cells have more mini ‘organs’ than researchers thought − unbound by membranes, these rogue organelles challenge biology’s fundamentals
- 5The most effective method to Use an Internet Showcasing Degree for Advanced Predominance
- Mountain Trekking on a Tight spending plan: Tracking down the Right Bicycle
- Defeating An inability to embrace success in Scholarly world: Individual Victories
- The most effective method to Make a Dazzling Site in 5 Basic Advances
- Looter indicted after pretending to be emergency worker at Dimona rocket crash site
- The 15 Most Compelling Books in History
- How does spider venom damage human cells? Researchers uncover the killer mechanism of recluse spider toxin
- Instructions to Pick the Best Course for Your Next Waterway Voyage: Objections, Views, and Social Encounters
- Dominating Capable Mastercard Utilization: Key Contemplations
- A Manual for Nations to Head out To
